A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

Marie Lindgren(Umeå University), Björn Andréasson(NU Hospital Group), Anna Hugosson(Skaraborg Hospital), Waleed Ghanima(Oslo University Hospital), Jan Samuelsson(Karolinska University Hospital), Peter Johansson(Linköping University), Håvar Knutsen(Akershus University Hospital), Maria Åström(Örebro University Hospital), Lars Nilsson(Skåne University Hospital), Elisabeth Ejerblad(Uppsala University)

Blood

December 6, 2014

10.1182/blood.v124.21.1861.1861

Cited by 3

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

|Blood|2008|447

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

|Blood|1998|306

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244